Several different high-dose therapy (HDT) conditioning regimens have been used for non-Hodgkin's lymphoma (NHL), such as BEAM (carmustine, etoposide, cytosine arabinoside, melphalan), BEAC (carmustine, etoposide, cytosine arabinoside, cyclophosphamide), and CBV (cyclophosphamide, carmustine, etoposide). Carmustine is an active drug in the HDT of NHL. Introduction of i.v. BU as an alternative to oral BU rekindled interest in optimizing the conditioning regimen to improve treatment outcome after allogeneic hematopoietic SCT for myelogenous leukemia.
1,2 The use of i.v. BU and CY suggested a lower incidence of serious hepatic veno-occlusive disease (VOD) and other treatment-related serious adverse events compared with what would be expected after oral BU and CY. 3 Once-daily i.v. BU is convenient to give, well-tolerated, efficacious and reduced toxicity. The BU, melphalan and thiotepa (BuMelTT) regimen has shown high activity in the treatment of patients with breast cancer, ovarian cancer, aggressive lymphoma and relapsed Hodgkin's disease. [4] [5] [6] Given the limited toxicity observed with i.v. BU and the known activity of BuMelTT regimen in NHL, we developed a protocol using once-daily i.v. BU/melphalan/ thiotepa regimen as a conditioning for HDT in the patients with high-risk or relapsed NHL. another patient died on day 74 due to sepsis without recovery of plts. The remaining patients achieved an ANC4500/mm 3 at a median of 10 days (range 9-30) and an unsupported plt count of 420 000/mm 3 at a median 20 days (range 11-35) after infusion of PBSC. Grade 3-4 regimen-related toxicities occurred in nine of 13 (69.2%) patients, mainly including mucositis, GI and hepatic toxicity. Six patients (46%) developed hepatic VOD including one severe type and three patients documented infections (klebsiella pneumonia, streptococcal pneumonia and sepsis due to MRSA and CMV bacteremia), one died of sepsis on post-transplant day 74. In all, one patient was not evaluable for response because of septic death. Four (80%) out of five patients with PR state before HDT achieved CR after HDT and one out of seven patients with CR state progressed during HDT; the remaining 10 out of 12 patients achieved or maintained CR after HDT. During the follow-up period (median 312 days, range 74-467), Table 1 Clinical data of 13 patients undergoing HDT using ivB-MT regimen followed by autologous SCT in the patients with high-risk or relapsed NHL CR  CR  193  193+  193+  3  3  0  3  No  8  M  58  DLBCL  PR  CR  237  102  237  3  0  0  1  No  9  F  36  PTCL  CR  CR  375  375+  375+  2  3  3  3  Yes  10  M  39  ALCL  CR  PD  127  30  127  1  2  2  2  Yes  11  F  52  DLBCL  PR  CR  319  104  319+  3  3  1  1  Yes  12  F  60  AIBTL  CR  NA  74  NA  74  0  4  3  3  Yes  13  F  52  DLBCL  CR  CR  288  288+ four patients relapsed after CR and EFS was 60, 102, 104 and 203 days, respectively ( Table 1) . The BuMelTT regimen was well tolerated in patients with aggressive NHL or relapsed HD, and results were at least equivalent to other published regimens, including six TBI-based regimens. Lee et al. 7 showed that VOD after BuMelTT was less frequent and less severe and developed later than VOD after a historical CY-based regimen. But recent retrospective comparison revealed BuMelTT regimen appeared to be equally effective but grade 3-4 mucositis, pulmonary toxicity, cardiac toxicity and liver toxicity were more frequent with BuMelTT regimen than BEAM regimen. 8 In this study, a regimen of once-daily i.v. BU combined with melphalan and thiotepa followed by autologous PBSC was administered to patients with highrisk or relapsed NHL. Similar to the previous study, 8 grade 3-4 mucositis and liver toxicity occurred in 65% and VOD developed in 46%. It is assumed that such toxicities may be relevant to regimens with triple alkylating drugs. Despite the comparable efficacy, we conclude that i.v. BU/ melphalan/thiotepa regimen was too toxic to our patients and this protocol was closed at our institutions.
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